The first and only FDA-authorized treatment for opioid exposed newborns with neonatal opioid withdrawal syndrome (NOWS). Prapela is a breakthrough noninvasive stimulation therapy that naturally improves breathing and oxygenation in newborns. Based on a field of science called Stochastic Resonance, our precise and gentle stimulation improves breathing rhythm and lung function in newborns. Since 2017, we've received over $8M in awards and grants funding the clinical evaluation of our therapy to improve the treatment of opioid-exposed newborns and preterm infants with apnea of prematurity. For more information, visit prapela.com medical device, Pediatrics, neonatology, neonatal intensive care, therapy, apnea of prematurity, …

66 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity. Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio. Biotechnology, Ultra Sensitive Immunoassays, and research

203 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

World leaders, pioneers and advocates in clinically validated, safe and effective #DigitalTherapeutics. We are global pioneers in digital therapeutics, successfully launching our first product in 2001. Our mission is to develop clinically validated digital therapeutics that empower patients, payers, and physicians with effective, FDA cleared products that have the same effect sizes as drugs. Our products are created by our team of multidisciplinary experts, covering all competencies required to develop, launch and maintain top-of-class products for major markets. Our team includes experienced physicians and psychotherapists, clinical scientists experienced in orchestrating Phase II & III trials, IT and software engineers, regulatory …

117 similar entities Type: SMB Activities: healthtech Technologies: Data Analytics

Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using …

240 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

343 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The leading experts in cancer cell capture and analysis from liquid biopsies ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE’s commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. …

277 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

A Sustainable Platform for Specialty Pharma. As a globally operating company headquartered in Germany, CHEPLAPHARM has established a leading and sustainable platform for specialty pharma during the past two decades. We invest worldwide in well-established pharmaceutical brands which have been developed and introduced by research-based pharmaceutical companies. Our deep expertise in this field enables us to sustain the value of these brands for patients and the medical community. In this way we help the research-based pharmaceutical industry divest from older products so they can focus resources on innovation and new product pipelines. This is how we ACHIEVE MORE together. Specialty …

120 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections …

236 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Guiding Pharmaceutical and Consumer Healthcare Companies to Success Pharmaceutical and consumer healthcare companies work within dynamic, sometimes unpredictable, regulatory and commercial environments. Pinney Associates' multidisciplinary teams anticipate your scientific and policy obstacles while guiding you toward regulatory and marketplace success. Pharmaceuticals, Risk Management, Abuse Liability Testing, Rx to OTC Switch, In vitro, Abuse potential assessment, Consumer healthcare, Consumer insights, Business development, FDA, CNS active drugs, Regulatory, Over-the-counter medicines, OTCs, Nonprescription drugs, Dietary supplements, Regulatory Strategy, Clinical Development, Eight Factor Analysis 8FA, Abuse Deterrent Formulation Evaluation, Postmarketing Surveillance, Risk Evaluation and Mitigation Strategies, REMS, Target Product Profiles, Scientific Assessment and Review, …

103 similar entities Type: SMB Activities: biotech deeptech martech regtech Technologies: Synthetic Biology

Power Your Health Di&Care is a French company dedicated to the development and marketing of “digital medicines” in the field of sleep and mental health. Our treatments are based on reference therapies in the management of these diseases. health, mental health, digital medicines, healthcare professionals, sleep specialists, IUD Sleep, and Doctors of Pharmacy

214 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

From Sea to Pharmacy Perha Pharmaceuticals is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors and developing them up to proof-of-concept in man. Perha Pharma focuses its research on two main diseases: cognitive disorders associated with Down syndrome (DS) and Alzheimer’s disease (AD), and hearing loss (HL) induced by ototoxic products. The first proof-of-concept in man should be achieved in both pathologies through niche indications: cognitive deficits in DS and hearing loss induced by cis-platin or aminoglycoside antibiotics. Perha Pharma was co-founded in April 2019 by Dr Laurent MEIJER, Chairman & CSO, former distinguished Director …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making Pharma democratic. Nosty is a decentralized platform where stakeholders in drug development work together to bring new therapeutics to patients faster and more efficiently than ever. The platform enables leading researchers and labs to raise fund among patients and the general public by turning IP and its development into a liquid and easily investable asset. The project is led by a team of serial entrepreneurs and professionals from the pharmaceutical industry, based in US and Europe.

63 similar entities Type: Startup Activities: deeptech biotech Technologies: SaaS

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Oréus, creator of PDA. Oréus has been creating PDA (Preparation of Doses to Administer) solutions that respond to the daily problems of healthcare personnel for more than 20 years. Creator of the first single-use compartmentalized pillbox as well as the computer-assisted manual PDA system. We innovate year after year to design ever more efficient solutions, responding to the reality on the ground in pharmacies and in medical establishments (18 patents filed). Our mission? Support you in the fight against poor compliance among your residents and/or chronic patients. Our promises: - Advanced security and traceability of the entire drug circuit, - …

126 similar entities Type: SMB Activities: healthtech Technologies: Cybersecurity

Pain relief at the touch of a finger Ethimedix is a healthcare technology company that offers a patented and pragmatic solution to fight against opioid misuse and dependence. Our flagship product, the SmartBottle, is a secure and efficient alternative to Opioid pills and PCA (PatientControlled Analgesia) pumps, utilizing biometric technology to dispense oral liquid opioids safely.

91 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Tarian Pharma's mission is to develop new drugs that ensure optimized cancer treatment by protecting cancer patients from side effects that would lead to dose reductions or discontinuation. This approach is designed to increase patients' chances of recovery and survival. Tarian Pharma was created by two dermatologists and a pharmacist, with more than 75 years of experience in the pharmaceutical industry and having been actively involved in the development and marketing of more than 15 new drugs in Europe, the United States and Asia.

107 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineering Biological Alpha Pheiron is an applied AI lab dedicated to Biological Alpha: the ability to know what biology will work in humans early enough to change the outcome of a drug program. We underwrite biology risk against clinical outcomes and use the edge to select and develop drug programs with the highest probability of success. At today's pace, humanity will wait 500 years for every known disease to have a cure. Twenty generations of patients. Pheiron compresses this timeline by radically increasing the drug-per-dollar output. 500 years is too long. We publish predictions on selected upcoming clinical readouts to …

70 similar entities Type: Startup Activities: healthtech it services Technologies: A.I.

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

443 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Changing lives with next generation peptide therapeutics At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases. Our …

186 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

NEW FRONTIERS IN NEUROSCIENCE Neurentis PLC is a late-clinical stage UK specialty pharma company, focusing on neuroscience and specialising in the development of novel treatments for mental health and other neurological and psychiatric diseases. Our product pipeline is balanced with an advanced lead drug for the treatment of Treatment-Resistant Depression (TRD) in the last stages of drug development as well as earlier stage drug candidates in collaboration with research institutions and other companies. The company is run by experienced ex-pharma industry executives, with more than 35 years’ experience in the sector each. The company’s low-risk commercial strategy is to commercialize …

382 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Fighting chronic and fatal diseases Tirecat Health is a company developing a family of novel polymers with amazing potential in the healthcare field. We are propelled with purpose to fight chronic and fatal diseases affecting patients worldwide using our revolutionary technology to improve their quality of life. In order to make this purpose a reality, the company is preparing to move towards the clinical phase to demonstrate the astonishing results seen in preclinical trials.

300 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

www.xspraypharma.com Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients’ quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval …

76 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

EryPharm is a biotech start-up company dedicated to the development and the operation of a large-scale process for the production of Red Blood Cells from stem cells. The technology has been developed by Dr. Luc Douay and his team at the Paris Sorbonne university. You can contact EryPharm through our website: http://erypharm.com/contact.html Or you can contact Loïc Tron directly: www.linkedin.com/in/loictron

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New therapies for neurodegenerative diseases Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more AlzeCure Pharma is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such …

204 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Children with rare diseases deserve therapeutic answers ORPHELIA Pharma is a French pharmaceutical company based in Paris and Lyon that develops and markets medicines for the treatment of pediatric orphan diseases. ORPHELIA Pharma‘s mission is to provide patients with essential products in the fields of epilepsy and pediatric oncology, with formulations adapted to the pediatric population. With one drug approved in the European Union and one product in late-stage clinical development, ORPHELIA Pharma has recently established regional agreements in the European Union, the USA and China and conducts research projects through academic and industrial partnerships. Neurology, Pediatry, Orphan drug, and …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Medincell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition …

577 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

New Natural & Ethical Anti Inflammatory Pharmaceutical Products Natural Products with Proven Health Claims For PETS. Pomega develops a novel, safe, ethical and non-toxic therapy that retards disease progression by inhibiting cartilage breakdown at an earlier stage. Product is developed by skilled pharmacist under drug standards frame First product coming out the pipeline is Ω-344 Product , a patented fruit extract with strong anti inflammatory properties osteoarthritis , anti inflammatory, fruit extract, inflammation, arthritis, biotech, NSAIDs, pain, animal, dogs, pets, wellness, healthcare, petfood, and cats

117 similar entities Type: Startup Activities: pettech deeptech biotech Technologies: Synthetic Biology

An innovative drug discovery technology Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease:  oncology (failure rate of 29.5%),  neurology (failure rate of 14%),  and infectious diseases (failure …

283 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovators in vaginal drug delivery Calla Lily Clinical Care is a British medical device startup developing Callavid®: a leak-free, convenient and dosage-confident delivery platform for vaginally-delivered drugs. We are initially focused on delivering progesterone for miscarriage prevention and IVF, where there is an unmet need for a patient-friendlier means of drug administration during an already stressful fertility journey. Progesterone prescriptions have significantly increased following the Nov 2021 update to internationally-renowned NICE’s guidance on miscarriages. Callavid® can also deliver menopausal treatments, targeted cancer treatments, and live biotherapeutics (LBPs) cutting antibiotic usage and reducing the spread of antimicrobial resistance (AMR). For pharmaceutical …

81 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Unlock cells. Deliver innovation. PEP-Therapy is a Paris-based biotechnology company developing next-generation therapies using our intracellular drug delivery shuttle. Our technology platform enables us to address the previously undruggable intracellular space with multiple payloads such as peptides, proteins, antibodies, and nucleic acids. As a demonstrator, PEP-010, our first drug candidate developed in oncology, is a pro-apoptotic peptide which has shown anti-tumoral activity and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Tailor-designed drug implants ​for local treatments. Founded by Truffle Capital. PK MED is a pioneering French biotechnology company founded in 2019 in Lyon, France, and supported by Truffle Capital, a leading European venture capital firm specializing in life sciences. We develop innovative biodegradable injectable micro-implants and advanced drug delivery technologies designed to address critical healthcare challenges. Our expertise spans rheumatology and novel cell homing approaches aimed at improving the success of bone marrow transplantation. Built on a team of experienced and passionate experts in pharmaceutical sciences, drug delivery, and biomaterials engineering, PK MED combines scientific excellence with innovation to develop …

98 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

We cultivate reciprocal relationships with anyone who crosses our path We are Napo Therapeutics: an European pharmaceutical company, a young start-up led by a team of experienced professionals. Our mission is to improve the quality of life of people suffering from rare diseases and pathologies with a strong unmet medical need through innovative solutions. Our name reflects our story: The Napo River crosses the territories of the Amazon where the Croton lechleri tree grows – the plant from which we extract the sap that contains a precious active ingredient. We are investigating an innovative and first-in-class drug thanks to the …

187 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

616 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

🫁 Improving the health and lives of patients through effective, safe and convenient inhaled drug delivery PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops®. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company’s leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global …

108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The premier active material science solutions expert that transforms ideas into market opportunities Aptar CSP Technologies (now Aptar Active Material Science) is the premier active material science solutions expert that transforms ideas into market opportunities, accelerates and de-risks the product development process, and provides complete solutions that improve consumers’ and patients’ lives. We offer a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. Our innovative solutions serve a variety of markets ranging from Pharmaceutical to Food Safety. Whether you need a solution …

107 similar entities Type: SMB Activities: deeptech manufacturing Technologies: Synthetic Biology

Find Your Next Blockbuster - Your single platform for accurate, objective, and timely intelligence Global biopharmaceutical drug patent and generic entry business intelligence. DrugPatentWatch Supports Critical Business Decisions: >Payers: Formulary and pharmacy & therapeutics (P&T) Anticipate future budget requirements and proactively identify generic sources > Branded pharmaceutical manufacturers Assess past successes of patent challengers and elucidate research paths of competitors > Generic manufacturers Inform portfolio management decisions on future drug development > Buyers, wholesalers, and distributors Predict branded drug patent expiration, identify generic suppliers, and prevent overstock of branded drugs > API manufacturers Obtain formulation and manufacturing information; identify final …

56 similar entities Type: SMB Activities: deeptech biotech legaltech Technologies: Data Analytics

Through conferences, community and market insights, we create partnerships that help advance the next pillar of medicine Phacilitate creates an environment where promising innovation can turn into the products that are changing the future of medicine. Recognised as the market leader in providing the life science sector with strategic insight, inspiration and unparalleled business networking, Phacilitate enables professionals to stay abreast of the issues driving life science innovation. #advancedtherapies #biotech #celltherapy #genetherapy Clinical Development, Cell Therapy, Gene Therapy, Oncology, Cancer, Precision Medicine, Biotech, Advanced Therapy, Biotechnology, and Life Sciences

214 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Building briteTM, the patient-pharma platform turning therapy support into real-world evidence 🌎 Every year, pharmaceutical and MedTech companies invest billions developing therapies that work in clinical trials and then lose visibility the moment those therapies reach real patients. XO Life exists to close that gap. briteTM is the leading digital meta-platform connecting pharmaceutical and MedTech manufacturers with their patients across the entire therapy journey. Unlike single-product apps that patients download once and abandon within weeks, briteTM works across every therapy, every indication, and every manufacturer within a single unified application, giving patients the verified support they need and giving manufacturers …

98 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: SaaS

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from …

79 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Ending malaria, rewriting the future MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Our vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease. Our success in research and access & product management comes from our extensive partnership network of over 375 pharmaceutical, academic and endemic-country partners in 50 countries. www.mmv.org www.facebook.com/medicinesformalaria www.twitter.com/medsformalaria www.youtube.com/user/MMVmeds4malaria http://plus.google.com/+mmvorgmedsformalaria Research and Development, Product Development Partnership (PDP), Medicines, and Malaria

110 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

We are Purespring. We are on a mission to radically transform the treatment of kidney diseases. Purespring, a clinical-stage precision nephrology company, is pioneering podocyte-targeted, genetically-driven therapies where unmet need is greatest. Our proprietary, category defining GlomTheraTM platform enables local administration of lower dose genetic therapies directly to the podocyte – a specialised kidney cell implicated in a majority of glomerular disease – with the potential for durable treatment effects. We’re developing a multi-asset pipeline focused on both monogenic and non-monogenic renal indications affecting large and underserved patient populations, including lead programmes: • PS-003: Advancing toward clinical development for Alport …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your Path to Better Brainwaves Pathwaves has become Supermind. Creator of Neural EmpowermentTM a proprietary, multi-dimensional and innovative methodology that uses the powerful principles of neuroplasticity along with integrative biofeedback and timeless healing modalities to help people attain an optimal state of mental, emotional, spiritual, and physical harmony. As a for-profit, social impact company, Pathwaves was established in 2016 with eight years of research and development preceding its launch. The Pathwaves team uses advanced technology to provide clients the tools to re-parent their cells utilizing their Brainwave Positioning SystemTM(BPS) – customized for each individual’s genetics, current biology, beliefs, life experiences, …

150 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Improving patient lives every day for a healthier tomorrow. Welcome to smartpatient, part of Redcare Pharmacy. We're a leading provider of direct-to-patient (DTP) solutions for the pharmaceutical industry. Through MyTherapy, the world’s most widely used medication management app with more than 12 million active patients, we enable pharma partners to engage and support patients directly, in a compliant and scalable way. Our integrated ecosystem connects digital activation, personalized support, medication dispensing, and real-world insights to deliver measurable outcomes across the entire patient journey. We're building the future of patient-centric healthcare. Join us in transforming direct-to-patient engagement worldwide. For more information, …

480 similar entities Type: Startup Activities: healthtech Technologies: Data Analytics

Recor Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise system is FDA approved in the United States, bears the CE mark, and is an investigational device in Japan, hypertension, medical device, and Intervention cardiology

99 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Collaborating with NIH & DoD to develop treatment options, targeting unmet needs in three multi-billion dollar markets. Virpax is pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur delivers local anesthetic at the wound/incision site, effectively managing post-operative pain for an extended 96 hours. Collaborating through Cooperative Research and Development Agreements (CRADA) and partnering with prestigious institutions like the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research/Department of Defense, we are committed to developing non-addictive treatments. Additionally, our involvement in the Epilepsy Therapy Screening Program (ETSP) underscores our …

145 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

Empowering healthcare organizations to deliver on their promise to put patients first. We work with you to thoughtfully integrate the patient perspective into your work, culture, processes, business decisions, and program activities, with the aim of improving patient outcomes and supporting your business goals. Rx4good supports every stage of the therapeutic pipeline, from pre-clinical development to post-launch. Our services elevate advocacy as a key driver of cross-functional business outcomes. Our three core pillars of our advocacy and engagement work include: - Research & Insight Generation - Patient Advocacy & Engagement - Communications & Mobilization Learn more at www.rx4good.com

63 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Clinical-stage lentiviral gene therapy company, powered by plato®. Our vision: bring personalized gene therapy worldwide Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease. Our proprietary plato® gene therapy platform is scalable for planned global commercialization. …

193 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Rebion provides a “Window to the Brain” to identify functional impairment of between the brain/eye pathway. Based on years of research and trials at major medical institutions, Rebion has harnessed the breakthrough Neural Performance Scanning (NPS) to precisely measure signal patterns that return from the brain, instantly determining if faulty signal processing is present. NPS portable point-of-care devices provide previously unavailable information for fast and impactful triage, making early disease detection, intervention and customized treatment more accessible. The company was founded by David Hunter, MD PhD, Ophthalmologist-in-Chief at Boston Children’s Hospital and FDA cleared in 2016. After more than 15 …

187 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital TherapeuticsTM, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such …

152 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: A.I. - Machine Learning

We provide healthcare professionals with a superior treatment option, ultimately improving patient outcomes. ArrayPatch Ltd is a clinical stage BioTech company. Our primary mission is to provide healthcare professionals with a superior treatment option, ultimately improving patient outcomes. This mission is centered around our innovative DerMap patent technology, a unique microneedle technology. The first product utilizing DerMap technology will address the fungal infection of the nail. ArrayPatch's robust product pipeline is also expanding into high-value indications including skin cancer, skin aging, migraines, and small peptide therapies for diabetics. Led by an experienced team with a strong international track record in …

63 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Developing life-changing, innovative therapies for diseases with unmet needs Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. Intranasal Drug Delivery, Migraine, Parkinson's Disease, CNS Therapeutics, and Autism

238 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses. As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com. Biotech, Drug Development, Pharmaceuticals, and RNAi

110 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

We do science TETRAPHARM is a Danish biopharmaceutical company that specializes in the development of pharmaceutical drugs aimed at the central nervous system and the immune system to treat neurological diseases and mental health disorders. In addition to a strong R&D pipeline, TETRAPHARM offers a suite of tailored end-to-end CDMO services that leverages the company's proprietary drug delivery technology, ZYNDIKATE®. Neuroscience and Precision Medicine

117 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology